Welcome to our dedicated page for Inotiv news (Ticker: NOTV), a resource for investors and traders seeking the latest updates and insights on Inotiv stock.
Inotiv, Inc. (NASDAQ: NOTV) is a contract research organization focused on nonclinical and analytical drug discovery and development services and research models and related products and services. The NOTV news feed on Stock Titan brings together company-issued updates, earnings announcements, strategic collaborations, legal and regulatory disclosures, and operational developments that shape the outlook for this preclinical services provider.
Investors and industry observers following Inotiv’s news can track segment trends in its Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) businesses, including commentary on safety assessment, general toxicology, biotherapeutic analysis, discovery and translational sciences, and non-human primate (NHP) product and service revenues. Regular earnings releases and preliminary results updates provide insight into revenue mix, operating performance, backlog, and book-to-bill ratios across these segments.
Inotiv’s news flow also covers strategic initiatives such as its collaboration with VUGENE to integrate an AI-enabled bioinformatics and computational platform into its Discovery & Translational Sciences Division, and its initiative to leverage LifeNet Health’s TruVivo system to incorporate human-relevant in vitro models into its disease pharmacology offering. These items offer context on how the company is incorporating new approach methodologies and data-driven tools into early-stage research support.
Regulatory and legal developments are another key component of NOTV news. Filings and press releases have addressed matters such as settlements of securities class action and derivative litigation, updates on investigations related to non-human primate importations, and disclosures about a cybersecurity incident and related privacy class actions. Capital structure updates, including engagement of financial advisors to explore debt refinancing alternatives and activity on credit facilities, also appear in the company’s communications.
By reviewing the NOTV news page, readers can follow how Inotiv communicates its financial results, operational progress, collaborations, risk factors, and governance changes over time, all directly based on its public disclosures.
Inotiv (NASDAQ: NOTV) will report fiscal 2026 first quarter results for the period ended December 31, 2025, on Monday, February 9, 2026, before the market opens.
The company will host a conference call the same day at 8:30 a.m. Eastern Time with domestic and international dial‑in access and a live webcast. An online replay will be available in the Investors section of Inotiv's website.
Inotiv (NASDAQ: NOTV) announced on January 13, 2026 a strategic initiative to integrate LifeNet Health’s patented TruVivo® platform into its Discovery and Translational Sciences (DTS) business.
The TruVivo® system uses primary human hepatocytes with human-derived feeder cells to build physiologically relevant in vitro models intended to improve translational predictivity. Inotiv said the integration will align preclinical models more closely with human biology and enable expansion of human-relevant tissue models beyond the liver to support clients across a range of diseases.
The companies framed the collaboration as advancing new approach methodologies to accelerate development of safer, more effective therapies.
Inotiv (NASDAQ: NOTV) announced a strategic collaboration with VUGENE on December 11, 2025 to integrate VUGENE’s cloud-based AI/ML multi-omics bioinformatics platform into Inotiv’s Discovery & Translational Sciences Division.
The partnership aims to accelerate AI-assisted drug discovery by improving interpretation of epigenomic, proteomic, and other molecular datasets to better predict drug efficacy and safety in early-stage research. Inotiv said the integration will enable more efficient, data-driven decision making for client discovery programs, while VUGENE expects broader application of its computational technologies in real-world research settings.
Inotiv (Nasdaq: NOTV) reported Q4 FY2025 revenue of $138.1M (+5.9% YoY) and FY2025 revenue of $513.0M (+4.5% YoY). Q4 operating loss narrowed to $6.8M and FY operating loss improved to $30.9M (down 64.2% YoY). Adjusted EBITDA was $11.8M (8.5% of revenue) in Q4 and $34.0M (6.6%) for FY2025. DSA revenue grew 15.7% in Q4 and DSA backlog was $138.2M at Sept 30, 2025. The company sold two U.S. properties to repay term loan principal, engaged Perella Weinberg Partners to explore refinancing, and disclosed a August 2025 cybersecurity incident with potential data access under evaluation.
Inotiv (NOTV) ranked 182nd on the 2025 Deloitte Technology Fast 500™ announced Nov. 25, 2025. The company reported 448% revenue growth from fiscal year 2021 to fiscal year 2024, the measurement period for the ranking.
Inotiv said the growth reflects strategic acquisitions, the development of complementary services, and a unified, client-focused CRO model. This is Inotiv’s third consecutive year on the Fast 500 list after prior rankings of 127th (2023) and 138th (2024).
Inotiv (NASDAQ: NOTV) will release fiscal 2025 fourth quarter and full year results for the period ended September 30, 2025 on Wednesday, December 3, 2025 after market close. Management will host a conference call the same day at 4:30 p.m. Eastern Time to discuss results.
Dial-in options include 1-800-225-9448 (Domestic) and 1-203-518-9708 (International) with conference ID INOTIV. A live webcast and an online replay will be available in the Investors section of the company website.
Inotiv (NASDAQ: NOTV) reported preliminary, unaudited Q4 FY2025 revenue of $137.5M–$138.5M and preliminary FY2025 revenue of $512.5M–$513.5M. Management said Discovery and Safety Assessment (DSA) services grew sequentially in Q4 and were up 60% year-over-year. Anticipated DSA backlog was approximately $138.0M at September 30, 2025, with book-to-bill ~1.08x for Q4 and ~1.05x for FY2025. Results are estimates and subject to year-end accounting and audit completion. The company updated its Jefferies Global Healthcare Conference presentation time to 11:00 AM GMT on Nov 18, 2025.
Inotiv (NASDAQ: NOTV) announced that management will participate in three investor conferences in November 2025: the UBS Global Healthcare Conference (Palm Beach Gardens, FL) on Nov 10–11, 2025 with 1-on-1 meetings; the Jefferies Global Healthcare Conference (London) on Nov 18, 2025 at 4:00 PM GMT / 11:00 AM ET with a presentation and 1-on-1 meetings (webcast link provided); and the Craig-Hallum Alpha Select Conference (New York) on Nov 18, 2025 with 1-on-1 meetings.
Company participants include Robert Leasure Jr., President & CEO, and Beth Taylor, CFO. Institutional investors should contact their sales representatives to schedule meetings.
Inotiv (NASDAQ:NOTV), a leading contract research organization focused on nonclinical drug discovery services and research models, announced its participation in three upcoming investor conferences in September 2025.
CEO Robert Leasure Jr. and CFO Beth Taylor will attend the H.C. Wainwright Global Investment Conference (September 10), the Baird Global Healthcare Conference (September 9), and the Lake Street Capital Markets Best Ideas Growth Conference (September 11). All events will take place in New York, NY, featuring presentations and one-on-one meetings with institutional investors.
Inotiv (NASDAQ:NOTV) reported strong Q3 FY2025 financial results with revenue increasing 23.5% to $130.7 million. The growth was driven by a 34.1% increase in Research Models & Services (RMS) revenue to $82.5 million and an 8.9% increase in Discovery & Safety Assessment (DSA) revenue to $48.2 million.
The company reduced its net loss to $17.6 million (13.5% of revenue) compared to $26.1 million in Q3 FY2024. Adjusted EBITDA improved significantly to $11.6 million (8.9% of revenue) from $0.1 million year-over-year. DSA backlog stood at $134.3 million with a book-to-bill ratio of 1.07x.
Notable developments include the SEC concluding its investigation related to non-human primate importations without recommending enforcement action, and a $10 million accrual for ongoing securities lawsuits, expected to be fully recovered through insurance.
FAQ
What is the current stock price of Inotiv (NOTV)?
What is the market cap of Inotiv (NOTV)?
